Semaglutide to Reduce Atrial Fibrillation Burden
NCT05209165 on ClinicalTrials.gov · last registry update 2022-10-27
132 participants. Due to report May 2027, alongside 42 other tracked readouts that quarter. Primary outcome, as filed: Atrial fibrillation burden. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for atrial fibrillation — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- SUSPENDED
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- San Francisco Veterans Affairs Medical Center
- Sponsor type
- Fed
- Enrollment
- 132
- Started
- 2023-05
- Primary completion
- 2027-05 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Atrial fibrillation burden
Conditions studied
Atrial Fibrillation · Obesity · Overweight
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.